3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
1
Influenza, Human
1
Interventions
Influenza Vaccines
6
trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine
2
Vaccines
2
thymoglobulin
1
fludarabine
1
baloxavir
1
SARS-CoV-2 inactivated vaccines
1
Rituximab
1
Oseltamivir
1
Nivolumab
1
Melphalan
1
Levetiracetam
1
Lenalidomide
1
Ipilimumab
1
Fluzone High-Dose
1
Cyclophosphamide
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Influenza, Human
×
Fluzone High-Dose
×
Clear all
NCT01666782
2016-06-24
IMMUNE
Rochester General Hospital
Phase 2
Completed
105 enrolled
10 charts